7LAB
 
 | |
7LAA
 | |
5KIT
 | |
7LD1
 | |
7LCN
 | |
7K4I
 | | Human Arginase 1 in complex with compound 06. | | 分子名称: | 3-[(1~{S},2~{S},5~{R})-2-carboxy-6-thia-3-azabicyclo[3.2.0]heptan-1-yl]propyl-$l^{3}-oxidanyl-bis(oxidanyl)boranuide, Arginase-1, MANGANESE (II) ION | | 著者 | Palte, R.L. | | 登録日 | 2020-09-15 | | 公開日 | 2021-10-06 | | 最終更新日 | 2023-10-18 | | 実験手法 | X-RAY DIFFRACTION (1.98 Å) | | 主引用文献 | Comprehensive Strategies to Bicyclic Prolines: Applications in the Synthesis of Potent Arginase Inhibitors.
Acs Med.Chem.Lett., 12, 2021
|
|
7K4J
 | | Human Arginase 1 in complex with compound 51. | | 分子名称: | 3-[(1~{S},2~{S},5~{R})-2-carboxy-3,6-diazabicyclo[3.2.0]heptan-1-yl]propyl-$l^{3}-oxidanyl-bis(oxidanyl)boranuide, Arginase-1, MANGANESE (II) ION | | 著者 | Palte, R.L. | | 登録日 | 2020-09-15 | | 公開日 | 2021-12-01 | | 最終更新日 | 2023-10-18 | | 実験手法 | X-RAY DIFFRACTION (1.94 Å) | | 主引用文献 | Comprehensive Strategies to Bicyclic Prolines: Applications in the Synthesis of Potent Arginase Inhibitors.
Acs Med.Chem.Lett., 12, 2021
|
|
7K4H
 | | Human Arginase 1 in complex with compound 04. | | 分子名称: | 3-[(1~{R},5~{S},8~{R})-5-carboxy-2,6-diazabicyclo[3.2.1]octan-8-yl]propyl-$l^{3}-oxidanyl-bis(oxidanyl)boranuide, Arginase-1, MANGANESE (II) ION | | 著者 | Palte, R.L. | | 登録日 | 2020-09-15 | | 公開日 | 2021-12-01 | | 最終更新日 | 2023-10-18 | | 実験手法 | X-RAY DIFFRACTION (1.65 Å) | | 主引用文献 | Comprehensive Strategies to Bicyclic Prolines: Applications in the Synthesis of Potent Arginase Inhibitors.
Acs Med.Chem.Lett., 12, 2021
|
|
7K4K
 | | Human Arginase 1 in complex with compound 52. | | 分子名称: | 3-[(3~{a}~{S},4~{S},6~{a}~{R})-4-carboxy-2,3,4,5,6,6~{a}-hexahydro-1~{H}-pyrrolo[2,3-c]pyrrol-3~{a}-yl]propyl-$l^{3}-oxidanyl-bis(oxidanyl)boranuide, Arginase-1, MANGANESE (II) ION | | 著者 | Palte, R.L. | | 登録日 | 2020-09-15 | | 公開日 | 2021-12-01 | | 最終更新日 | 2023-10-18 | | 実験手法 | X-RAY DIFFRACTION (2.27 Å) | | 主引用文献 | Comprehensive Strategies to Bicyclic Prolines: Applications in the Synthesis of Potent Arginase Inhibitors.
Acs Med.Chem.Lett., 12, 2021
|
|
7K4G
 | | Human Arginase 1 in complex with compound 01. | | 分子名称: | 3-[(2~{S},3~{R})-2-carboxypyrrolidin-3-yl]propyl-$l^{3}-oxidanyl-bis(oxidanyl)boranuide, Arginase-1, MANGANESE (II) ION | | 著者 | Palte, R.L. | | 登録日 | 2020-09-15 | | 公開日 | 2021-12-01 | | 最終更新日 | 2023-10-18 | | 実験手法 | X-RAY DIFFRACTION (1.8 Å) | | 主引用文献 | Comprehensive Strategies to Bicyclic Prolines: Applications in the Synthesis of Potent Arginase Inhibitors.
Acs Med.Chem.Lett., 12, 2021
|
|
7RRC
 | | IDO1 IN COMPLEX WITH COMPOUND 14 | | 分子名称: | Indoleamine 2,3-dioxygenase 1, N-(4-fluorophenyl)-3-{4-[4-(hydroxymethyl)-6-(trifluoromethyl)pyridin-3-yl]phenyl}oxetane-3-carboxamide | | 著者 | Lesburg, C.A. | | 登録日 | 2021-08-09 | | 公開日 | 2022-03-16 | | 最終更新日 | 2022-05-11 | | 実験手法 | X-RAY DIFFRACTION (2.18 Å) | | 主引用文献 | Oxetane Promise Delivered: Discovery of Long-Acting IDO1 Inhibitors Suitable for Q3W Oral or Parenteral Dosing.
J.Med.Chem., 65, 2022
|
|
7RRB
 | | IDO1 IN COMPLEX WITH COMPOUND 9 | | 分子名称: | 3-[4-(6-cyclopropylpyridin-3-yl)phenyl]-N-(4-fluorophenyl)oxetane-3-carboxamide, Indoleamine 2,3-dioxygenase 1 | | 著者 | Lesburg, C.A. | | 登録日 | 2021-08-09 | | 公開日 | 2022-03-16 | | 最終更新日 | 2022-05-11 | | 実験手法 | X-RAY DIFFRACTION (2.69 Å) | | 主引用文献 | Oxetane Promise Delivered: Discovery of Long-Acting IDO1 Inhibitors Suitable for Q3W Oral or Parenteral Dosing.
J.Med.Chem., 65, 2022
|
|
5IME
 | | Crystal structure of P21-activated kinase 1 (PAK1) in complex with compound 9 | | 分子名称: | 8-(3-aminopropyl)-6-[2-chloro-4-(3-methyl-2-oxopyrazin-1(2H)-yl)phenyl]-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one, Serine/threonine-protein kinase PAK 1 | | 著者 | Li, D, Wang, W. | | 登録日 | 2016-03-06 | | 公開日 | 2016-05-25 | | 最終更新日 | 2023-09-27 | | 実験手法 | X-RAY DIFFRACTION (2.217 Å) | | 主引用文献 | Chemically Diverse Group I p21-Activated Kinase (PAK) Inhibitors Impart Acute Cardiovascular Toxicity with a Narrow Therapeutic Window.
J.Med.Chem., 59, 2016
|
|
7LJR
 | | SARS-CoV-2 Spike Protein Trimer bound to DH1043 fab | | 分子名称: | Fab DH1043 heavy chain, Fab DH1043 light chain, Spike glycoprotein | | 著者 | Gobeil, S, Acharya, P. | | 登録日 | 2021-01-30 | | 公開日 | 2021-03-31 | | 最終更新日 | 2024-03-06 | | 実験手法 | ELECTRON MICROSCOPY (3.66 Å) | | 主引用文献 | The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates.
Biorxiv, 2021
|
|
6IZ5
 | |
7BH8
 | | 3H4-Fab HLA-E-VL9 co-complex | | 分子名称: | 3H4 Fab heavy chain, 3H4 Fab light chain, Beta-2-microglobulin, ... | | 著者 | Walters, L.C, Rozbesky, D. | | 登録日 | 2021-01-10 | | 公開日 | 2022-04-13 | | 最終更新日 | 2024-01-31 | | 実験手法 | X-RAY DIFFRACTION (1.8 Å) | | 主引用文献 | Mouse and human antibodies bind HLA-E-leader peptide complexes and enhance NK cell cytotoxicity.
Commun Biol, 5, 2022
|
|
3LGP
 | |
8I2Q
 | |
8I2R
 | |
4R0U
 | |
4R0P
 | |
4R0W
 | |
7C8P
 | |
6RJ3
 | | Crystal structure of PHGDH in complex with compound 15 | | 分子名称: | 4-[(1~{R})-1-[(2-methyl-5-phenyl-pyrazol-3-yl)carbonylamino]ethyl]benzoic acid, D-3-phosphoglycerate dehydrogenase, SULFATE ION | | 著者 | Bader, G, Wolkerstorfer, B, Zoephel, A. | | 登録日 | 2019-04-26 | | 公開日 | 2019-08-07 | | 最終更新日 | 2024-01-24 | | 実験手法 | X-RAY DIFFRACTION (1.42 Å) | | 主引用文献 | Intracellular Trapping of the Selective Phosphoglycerate Dehydrogenase (PHGDH) InhibitorBI-4924Disrupts Serine Biosynthesis.
J.Med.Chem., 62, 2019
|
|
4WBX
 | | Conserved hypothetical protein PF1771 from Pyrococcus furiosus solved by sulfur SAD using Swiss Light Source data | | 分子名称: | 2-keto acid:ferredoxin oxidoreductase subunit alpha | | 著者 | Weinert, T, Waltersperger, S, Olieric, V, Panepucci, E, Chen, L, Rose, J.P, Wang, M, Wang, B.C, Southeast Collaboratory for Structural Genomics (SECSG) | | 登録日 | 2014-09-04 | | 公開日 | 2014-12-10 | | 最終更新日 | 2023-12-27 | | 実験手法 | X-RAY DIFFRACTION (2.301 Å) | | 主引用文献 | Fast native-SAD phasing for routine macromolecular structure determination.
Nat.Methods, 12, 2015
|
|
